Loading clinical trials...
Loading clinical trials...
An Observational Study of Enzyme Replacement Therapy-Naïve and Agalsidase Beta-Treated Fabry Disease Patients With GLA IVS4 919 G>A Mutation in Taiwan
Conditions
Locations
5
Taiwan
Investigational Site Number : 1580004
Taichung, Taiwan
Investigational Site Number : 1580005
Tainan, Taiwan
Investigational Site Number : 1580001
Taipei, Taiwan
Investigational Site Number : 1580003
Taipei, Taiwan
Investigational Site Number : 1580002
Taipei, Taiwan
Start Date
September 13, 2023
Primary Completion Date
September 10, 2026
Completion Date
September 10, 2026
Last Updated
March 21, 2025
NCT06941025
NCT07382128
NCT05923788
NCT05473637
NCT07277361
NCT04252066
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions